source
- AbbVie/Genmab’s Epkinly halves progression risk in frontline DLBCL trialA Phase 3 study of the bispecific antibody Epkinly combined with standard chemotherapy showed nearly a 50% reduction in the risk of disease progression or death compared with chemotherapy alone in…
- AbbVie and Genmab's Epkinly succeeds in late-stage first-line DLBCL trial, challenging Roche's PolivyAbbVie and Genmab announced that their T‑cell engager Epkinly met its primary endpoints in a late‑stage study evaluating first‑line treatment for diffuse large B‑cell lymphoma (DLBCL). The trial de…